In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- ...

Galectin Therapeutics Inc. (NASDAQ:GALT), a pharmaceutical company focused on the development of treatments for fibrotic disease and cancer with a market capitalization of $76.57 million ...

NORCROSS, Ga., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced additional results ...

Key Insights Galectin Therapeutics' significant individual investors ownership suggests that the key decisions ...

Galectin Therapeutics (NASDAQ:GALT) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents. This met the analyst estimate for EPS of ...

Galectin Therapeutics (GALT) announced additional results showing a statistically significant reduction in new varices in per-protocol patients enrolled in the U.S. from the NAVIGATE trial for ...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...

This graphic illustrates paracrine adhesion signaling on small extracellular vesicles, which secretes a protein called galectin-3, which promotes endocytosis so the vesicle can be absorbed into the ...

Detailed price information for Galectin Therapeutic (GALT-Q) from The Globe and Mail including charting and trades.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...